|

SHR-1701 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 1

Top Sponsors

  • Nanjing Tianyinshan Hospital1
  • Chinese PLA General Hospital1

Indications

  • Cancer2
  • Liver Disease1
  • Relapsed or Refractory Hodgkin Lymphoma1
  • Hepatocellular Carcinoma (HCC)1
  • Liver Cancer1

Other2 trials

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.